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Abstract — Aims: In randomized controlled trials with high internal validity, pharmacotherapy using acamprosate, naltrexone, and,
to a somewhat lesser extent, disulfiram has proved effective in preventing relapse in patients with alcohol use disorders (AUD).
There remains, however, a paucity of studies with sufficient external validity in which the effectiveness of pharmacotherapy in
clinical practice is investigated. This study aimed to make a contribution to close this gap in research. Methods: In this naturalistic,
prospective study, a comparison on indices of substance use, psychiatric symptoms, and treatment service utilization was carried
out using samples of 92 patients who received pharmacotherapy and 323 patients who did not receive pharmacotherapy following
discharge from 12 residential AUD programmes (index stay). Results: Patients that received pharmacotherapy were more likely
to use alcohol during the index stay and at the 1-year follow-up. Moreover, this patient group more readily utilized treatment
services during a 2-year period prior to and a 1-year period following index stay than patients who were not given pharmacotherapy.
Nevertheless, when pharmacotherapy was prescribed before first post-treatment alcohol use, it was associated with delay of alcohol
use, fewer relapses, and a reduced need for inpatient treatment. In many cases, however, medication was not prescribed until alcohol
use and relapse had occurred. The length of time to first alcohol use was longer, and the cumulative abstinence rate higher, for
disulfiram than for acamprosate, the latter being generally prescribed for more severely alcohol-dependent patients. Conclusions:
There is a need for further studies to probe the reasons why medication for relapse prevention is not prescribed upon discharge from
residential treatment and for less severely alcohol-dependent patients.
INTRODUCTION
Acamprosate, naltrexone, and disulfiram constitute the only
medications currently approved for pharmacotherapy in alco-
hol use disorders Alcohol Use Disorders (AUD). In a well-
designed, methodological analysis of 361 controlled clinical
trials of treatments for AUD, Miller and Wilbourne found
that the efficacy of two medications (i.e. acamprosate and
naltrexone) was equally high as that of psychosocial treat-
ments, such as brief intervention, motivational enhancement,
and several cognitive-behavioural interventions (CBI) (Miller
and Wilbourne, 2002). Acamprosate, a modulator of gluta-
matergic activity, is thought to reduce withdrawal relief crav-
ing by attenuating central nervous system hyperexcitability
due to lack of alcohol, which may, in turn, cause phys-
iological and psychological distress. Naltrexone, an opioid
antagonist, which weakens the positive effects of alcohol, is
considered effective against reward craving. In two compre-
hensive reviews of pharmacotherapy for AUD (Heinz et al .,
2003; Mann, 2004), it was concluded that acamprosate and
naltrexone both decrease relapse rates but not abstinence
rates. Whereas the efficacy of acamprosate did not appear
to be influenced by additional psychosocial treatment, phar-
macotherapy using naltrexone obtained better results in con-
junction with CBI than with supportive/12-step treatment
(Berglund et al ., 2003; Mann, 2004). These findings have
been confirmed in three recent and sound meta-analyses,
which provided evidence of small effect sizes for pharma-
cotherapy compared to placebo (d = 0.06–0.28) (Mann et al .,
2004; Berglund, 2005; Roozen et al ., 2005). In a random-
ized controlled study, Kiefer and colleagues found that the
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combination of acamprosate and naltrexone had the great-
est effect on relapse rates—greater than that of acamprosate
alone and placebo, although not any greater than that of nal-
trexone alone (Kiefer et al ., 2003). Similarly, Feeney and
colleagues reported in a matched controlled clinical study that
patients treated with a combination of acamprosate, naltrex-
one, and CBI (combination group) tended to achieve higher
abstinence rates than patients treated either with CBI alone or
with CBI and acamprosate (Feeney et al ., 2006). In addition,
the combination group reported more days to first breach of
abstinence than the group treated with CBI alone. No signif-
icant differences were found between the combination group
and the CBI and acamprosate group.
In contrast to the findings of these two single-site trials, the
results of the COMBINE study failed to support the combined
use of acamprosate and naltrexone (Anton et al ., 2006). This
randomized controlled clinical multisite trial evaluated the
efficacy of these two most promising pharmacotherapies, used
both singly and in combination, and also in conjunction
with psychosocial treatments, namely brief intervention with
medical management (Pettinati et al ., 2004) and a series of
the most effective CBI (Miller, 2004). Anton and colleagues
report that overall medical management with naltrexone or
CBI attained the best alcohol use outcome. Acamprosate
showed no evidence of efficacy, either when administered
alone or together with CBI. Patients receiving only CBI had
worse outcomes than those in the other groups. However,
effect sizes observed during treatment were small and largely
disappeared over the 1-year post-treatment period.
There is somewhat less evidence for the efficacy of
disulfiram alone compared to control groups (Miller and
Wilbourne, 2002). Berglund’s meta-analysis even revealed
an effect size of zero in placebo-controlled studies, while
determining a moderate effect size (d = 0.53) for disulfi-
ram when pharmacotherapy was paired with supervision or
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contingency management (Berglund, 2005). Ehrenreich and
colleagues—presenting results from an intensive long-term
outpatient programme for individuals suffering from chronic
alcoholism—determined that the relapse rate of patients who
were given disulfiram was considerably lower than that of
controls (30% vs 70%) (Ehrenreich et al ., 1997). Further-
more, Petrakis and colleagues found no differences in alcohol
use outcomes of dually diagnosed patients who had been
prescribed either disulfiram or naltrexone, a finding which
suggests that the medications had been of the same standard
(Petrakis et al ., 2005). Finally, Fuller and Gordis conclude
that the supervised administration of disulfiram is warranted
for patients struggling to achieve abstinence (Fuller and
Gordis, 2004).
The aforementioned findings are all based on methodologi-
cally sound efficacy studies with high internal validity, hence
allowing the conclusion to be drawn that a significant dif-
ference in outcome between treatment and control conditions
is causally linked to treatment. However, it is not a fore-
gone conclusion that a treatment providing good results in
an efficacy study will also work in clinical practice. For
example, applying typical patient exclusion criteria usually
results in patient samples that do not adequately reflect the
cross-section of AUD patients encountered in clinical prac-
tice, something that may compromise the generalizability of
the results (Humphreys and Weisner, 2000). It may, there-
fore, prove more expedient to conduct an effectiveness study
with sufficient external validity in order to determine which
treatment is most effective under field conditions (Seligman,
1995; Bu¨hringer, 2006). Such an evaluation should ideally
utilize a naturalistic, prospective, and multisite design that
capitalizes on realistic treatment selection and conditions. It
should furthermore enable patients to express their prefer-
ences for particular treatments, while maximising compliance
with treatment and minimizing attrition and crossover to non-
assigned programmes (Moos et al ., 1990b; Ogborne, 1995).
It is such an evaluation paradigm that underlies the Swiss
Multisite Study (SMS 2000), the aim of which is to identify
those characteristics of inpatient treatment programmes that
are associated with favourable outcome in AUD patients at the
1-year follow-up (Moggi et al ., 2007). The authors expanded
the focus of the SMS 2000 by examining: (i) which patient
characteristics (i.e. substance use, psychiatric symptoms,
and service utilization) are related to a higher likelihood
of medication for relapse prevention being prescribed; (ii)
whether prescribing medication is associated with outcome
indices; and (iii) whether acamprosate and disulfiram are
related to outcome indices in different ways.
MATERIALS AND METHODS
Procedure
The authors selected 12 standard-practice residential pro-
grammes for treating AUD patients, thereby capitalising on
realistic treatment conditions and typical treatment orienta-
tions in programmes representative for the German-speaking
part of Switzerland. On admission and after detoxification,
patients completed an intake information form (IIF) (Maude-
Griffin et al ., 1992), which enabled assessment of sociode-
mographic characteristics, indices of substance use and its
consequences, psychological and social functioning, treatment
motivation, prior involvement in outpatient treatment and self-
help activities, and the number of prior hospitalizations. At
discharge, patients completed a discharge information form
(DIF) (Maude-Griffin et al ., 1992), which enabled assess-
ment of indices of substance use, as well as psychological
and social functioning. The clinical diagnoses were discharge
diagnoses made by doctoral-level clinical staff. These diag-
noses included Axis I and Axis II disorders as well as medical
conditions and were based on the guidelines of the Interna-
tional Classification of Diseases, 10th Revision (Dilling et al .,
1991). At follow-up, about 1 year after discharge from the
index stay, patients completed a Follow-up Information Form
(FIF) (Maude-Griffin et al ., 1992), which enabled assessment
of content areas identical to those in the IIF. In addition,
patients were asked whether they had been prescribed any
medication to prevent alcohol relapse and, if yes, what med-
ication this was and when they had started taking it.
In Switzerland, only acamprosate and disulfiram are
approved, while naltrexone may be prescribed off-label. The
present study was approved by the Ethics Committee of the
Canton of Bern (Proposal No. 109/99).
Patients
All patients presenting substance use disorders (SUD) who
started an index stay in any of the 12 programmes were asked
to participate in the evaluation. A total of 805 out of 1088
patients (74.0%) agreed to participate. Of these, 587 (72.9%)
suffered from an AUD exclusively and were not diagnosed
with a SUD. Of this sample, 415 (70.7%) completed the forms
on admission, at discharge, and at the 1-year follow-up. All
the other patients dropped out of the respective programme
before detoxification, were unable to participate on medical
or language grounds, or, alternatively, refused to participate.
Patients who responded to all three measurements were
compared with non-responding patients on indices of demo-
graphic characteristics, substance use, and psychiatric symp-
toms and diagnoses. Respondents were slightly older than
non-respondents (46.3 vs 44.7 years; t = −2.38, df = 585,
P < 0.05) and were more likely to be female (34.0% vs
24.4%; χ2 = 4.74, df = 1, P < 0.05), married (39.8% vs
26.5%; χ2 = 8.48, df = 1, P < 0.01), and employed (58.7%
vs 47.0%; χ2 = 8.48, df = 1, P < 0.05). No differences were
found with respect to other indices.
Of the responding patients, 90.5% lived in their own
home or in a flat; mean length of education was 12.2 years
(SD = 2.90). Ninety two patients (22.2%) reported having
taken medication during the 1-year follow-up period, 313
patients (75.4%) had not been prescribed any pharmacother-
apy, and 10 (2.4%) did not give an answer. Disulfiram had
been prescribed to 65 patients (70.7%), acamprosate to 16
(17.4%), naltrexone to 2 (2.2%), and 9 (9.9%) failed to specify
what medication they had received. 40.7% had been diag-
nosed with co-occurring mental disorders, i.e. 56.2% suffered
from a personality disorder, 34.9% from depression, 11.8%
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from an anxiety disorder, and 1.2% from a psychotic disor-
der (co-occurrence of multiple psychiatric disorders was also
possible).
Assessments
Assessment instruments from the IIF, DIF, and FIF, which did
not exist in German, were translated from English by a native
German-speaking PhD-level psychologist, and subsequently
back-translated by a native English-speaking PhD-level psy-
chologist. In those instances of discrepancies arising between
the original and back-translated English versions, the items
concerned were revised and adapted accordingly.
Alcohol and drug use. A total of 15 items were used
to assess the patients’ alcohol and drug use during the
preceding month. These items were adapted from the Health
and Daily Living Form (HDL) (Moos et al ., 1990a) and from
the Treatment Outcome Prospective Study (TOPS) (Hubbard
et al ., 1989). Patients were asked about how often and in
what amounts they consumed beer, wine, and spirits, and also
about the frequency of illicit drug use. The severity of alcohol
dependence was assessed by means of 9 items drawn from
the Alcohol Dependence Scale (alpha = 0.92) and modified
to correspond with DSM criteria for alcohol dependence
(Maude-Griffin et al ., 1992). Item responses ranged from
‘never’ (0) to ‘almost every day’ (4), on a scale from 0–36.
Substance use consequences (alpha = 0.80) were assessed
using 15 items, addressing, among other things, job, family,
or health issues (Maude-Griffin et al ., 1992). Item responses
ranged from ‘never’ (0) to ‘often’ (4), on a scale from 0–60.
Alcohol craving was assessed with 1 item from the German
version of the Situational Confidence Scale (Annis and Davis,
1988; Schindler et al ., 1997).
Treatment motivation was measured by means of the sum
scores as derived from the Determination and Action stages
as rated on the Stages of Change Readiness and Treatment
Eagerness Scale (SOCRATES) (Miller and Tonigan, 1996).
Each of these stages was assessed by 4 items, to which
responses ranged from ‘strongly disagree’ (0) to ‘strongly
agree’ (4), on a scale from 0–32. Cronbach’s alpha was 0.73.
Psychiatric symptoms were assessed by means of selected
items from the Brief Symptom Inventory (BSI) (Derogatis,
1993; German version: Franke 2000). Item responses ranged
from ‘not at all’ (0) to ‘extremely’ (4). Emotional distress
was measured by a combination of depression (alpha = 0.88)
and anxiety (alpha = 0.84; range = 0–24). Psychotic symp-
toms were measured by a combination of paranoid ideation
(alpha = 0.70; range = 0–20) and psychoticism (alpha =
0.72; range = 0–20).
Prior and post treatments were measured by quantifying
any in- or outpatient treatment for SUD or other psychiatric
disorders during a 2-year period before and a 1-year period
following index stay (coded as 1 = 1 or more, 0 = none), as
well as the number of outpatient sessions attended by patients.
To assess patient substance use and functioning, focus was
placed on the following outcome measures : (a) abstinence
from alcohol and drugs, as reflected by reports of no
alcohol and/or drug consumption (coded as 1 = abstinent,
0 = not abstinent); (b) time to first alcohol use, as defined
by the number of days to first alcohol use after index
stay; (c) relapse, as reflected by reports of relapse as per-
ceived by patients; (d) gram alcohol per regular drinking day ;
(e) substance use consequences ; (f) severity of alcohol depen-
dence; (g) craving ; (h) treatment motivation; (i) emotional
distress ; (j) psychotic symptoms ; and (k) in- or outpatient
treatment as a result of substance use or other psychiatric
disorders during the 1-year follow-up period.
Statistical procedures
χ2 for categorical data and t-tests for continuous data were
computed to compare the two groups of patients with/without
post-treatment medication on indices of alcohol use and
its consequences, craving, treatment motivation, psychiatric
symptoms, and service utilization. Kaplan-Meier survival
analyses were performed to determine whether the two patient
groups differed in terms of time to first alcohol use and
relapse, and whether there were any differences between
patients taking acamprosate and those taking disulfiram.
Effect sizes (ES) were estimated by calculating d* for
categorical data (Hasselblad and Hedges, 1995) and d for
continuous data (Cohen, 1988).
RESULTS
Patients taking post-treatment medication tended to be some-
what younger and more likely to have had outpatient treatment
for psychiatric disorders during the 2 years prior to index stay
than patients not taking post-treatment medication. The for-
mer patient group showed a slightly greater propensity to use
alcohol during index stay, as well as a significantly higher
probability to have had SUD inpatient treatment during the
2 years prior to index stay (Table 1). In addition, patients
(N = 48) medicated after their first alcohol use reported con-
suming more grams of alcohol per regular drinking day prior
to index stay than patients (N = 29) medicated before their
first alcohol use (206.3 g vs 139.7 g, t = 2.96, df = 70.28,
P < 0.01, ES = 0.65). Patients taking acamprosate (N = 16)
scored higher on the severity of alcohol dependence scale than
patients taking disulfiram (N = 61; 23.9 vs 18.5, t = 2.14,
df = 25.29, P < 0.01, ES = 0.59). No significant differences
were found either with respect to other demographic and
treatment characteristics or on alcohol use and psychiatric
symptoms indices.
Patients taking post-treatment medication were more likely
to have used alcohol and to have suffered relapses during
follow-up than patients without post-treatment medication.
The former patient group also consumed slightly larger
quantities of alcohol per regular drinking day, reported a
somewhat larger number of alcohol dependence symptoms,
and tended to suffer more heavily from emotional distress.
Moreover, they more clearly tended to take advantage of SUD
in- and outpatient treatment, and of outpatient treatment for
psychiatric disorders during the 1-year period following index
stay (Table 2).
It is self-evident that all patients medicated after their first
alcohol use had drunk, but only 55.2% of patients medi-
cated before a potential relapse reported some subsequent
alcohol use (χ2 = 25.89, df = 1, P < 0.001; ES = 1.42).
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Table 1. Comparison, at time of index stay, between patients with/without subsequent pharmacotherapy: patients’ demographic characteristics,
treatment service utilization, substance use, and psychiatric symptoms
Medicationa No medication Test ES
Patient characteristics at index stay %/M SD %/M SD t χ2 d d∗
Demographics
Age 45.0 8.84 47.0 9.42 1.80† — 0.22 —
Female (%) 24.1 — 75.9 — — 0.12 — 0.06
Male (%) 22.0 — 78.0 — — — — —
Married (% yes) 41.3 — 39.0 — — 0.08 — 0.05
Employed (% yes) 64.1 — 57.1 — — 1.19 — 0.16
Alcohol use
Alcohol in g per regular drinking day 177.3 111.80 163.5 105.15 1.08 — 0.13 —
Severity of alcohol dependence 20.1 10.14 18.9 10.41 1.01 — 0.12 —
Craving for alcohol 3.4 1.29 3.6 1.23 1.17 — 0.16 —
Treatment motivation 38.7 5.39 38.7 5.48 0.07 — 0.00 —
Alcohol use during index stay (% yes) 32.6 — 21.4 — — 4.33∗ — 0.32
Psychiatric symptoms
Emotional distress 14.2 8.53 14.0 9.87 0.15 — 0.02 —
Psychotic symptoms 9.9 6.47 9.5 6.91 0.15 — 0.06 —
Treatment (2 years prior to index stay)
Inpatient SUD (% yes) 55.4 — 35.5 — — 11.00∗∗∗ — 0.45
Outpatient SUD (% yes) 48.9 — 39.0 — — 2.50 — 0.22
Inpatient psychiatric disorders (% yes) 13.0 — 9.9 — — 0.45 — 0.17
Outpatient psychiatric disorders (% yes) 32.6 — 22.0 — — 3.74† — 0.30
Notes: aDue to missing data, N varies from 91–92 in the medication group and from 309–313 in the no medication group; SUD, Substance
Use Disorders; Test = Statistical test; ES, Effect size; M/%, Mean/Percent; SD, Standard deviation; t, t-test; χ2, Chi-square test; d, Cohen’s d; d∗,
Hasselblad & Hedges’ d∗.
† P < 0.10;
∗ P < 0.05;
∗∗∗ P < 0.001.
Table 2. Comparison, at time of 1-year follow-up, between patients with/without prior pharmacotherapy: outcomes
and treatment service utilization
Medicationa No medication Test ES
Outcomes and treatment %/M SD %/M SD t χ2 d d∗
Alcohol use outcomes
Alcohol use (% yes) 84.8 — 60.1 — — 18.19∗∗∗ — 0.72
Time to first alcohol use in daysb 72.0 77.21 78.8 80.64 0.63 — 0.09 —
Alcohol relapse (% yes) 67.4 — 29.8 — — 39.90∗∗∗ — 0.87
Alcohol in g per regular drinking day 66.7 92.37 44.9 73.45 1.98∗ — 0.26 —
Alcohol use consequences 7.8 8.00 6.5 7.66 1.41 — 0.18 —
Severity of alcohol dependence 6.8 9.60 4.6 7.62 1.99∗ — 0.25 —
Craving for alcohol 3.4 1.34 3.6 1.46 1.15 — 0.14 —
Treatment motivation 36.8 5.88 32.5 7.52 4.86∗∗∗ — 0.64 —
Psychiatric outcomes
Emotional distress 8.1 6.73 6.5 7.00 1.86† — 0.24 —
Psychotic symptoms 6.2 5.71 5.4 5.29 1.33 — 0.15 —
Treatment during follow-up
Inpatient SUD (% yes) 41.1 — 9.6 — — 47.65∗∗∗ — 1.04
Outpatient SUD (% yes) 70.8 — 38.5 — — 27.72∗∗∗ — 0.75
Inpatient psychiatric disorders (% yes) 6.7 — 3.3 — — 1.27 — 0.41
Outpatient psychiatric disorders (% yes) 32.2 — 18.4 — — 7.11∗∗ — 0.41
Notes: aDue to missing data, N varies from 83–92 in the medication group and from 301–313 in the no medication group.
b Only those patients who reported any alcohol use (N = 75 in the medication group and N = 181 in the no medication group); SUD, Substance
Use Disorders; Test = Statistical test; ES, Effect size; M/%, Mean/Percent; SD, Standard deviation; t, t-test; χ2, Chi-square test; d, Cohen’s d;
d∗, Hasselblad & Hedges’ d∗.
† P < 0.10;
∗ P < 0.05;
∗∗ P < 0.01;
∗∗∗ P < 0.001.
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While 78.7% of patients medicated after their first alcohol
use reported at least one alcohol relapse, the relapse rate
was a modest 37.9% for patients medicated before a potential
relapse (χ2 = 12.83, df = 1, P < 0.001, ES = 0.99). More-
over, 46.8% of patients medicated after their first alcohol use
had SUD inpatient treatment at least once, whereas such treat-
ment was given to only 20.7% of patients medicated before a
potential relapse (χ2 = 5.26, df = 1, P < 0.05, ES = 0.13).
Another finding was that, on average, patients taking acam-
prosate started drinking 51 days after index stay, while
this time span was 137 days for patients taking disulfiram
(t = 3.03, df = 33.28, P < 0.01, ES = 0.77). No other dif-
ferences between patient groups were found at the 1-year
follow-up.
The cumulative probability of abstinence during the 1-year
follow-up period—in terms of the number of days to first
alcohol use—was considerably higher for patients without
medication than for patients with medication (Fig. 1(a); log
rank = 21.54, df = 1, P < 0.001). No significant difference
was found, however, between the cumulative probability
of abstinence among patients who had received medication
before their first alcohol use, and among patients who
had not (Fig. 1(b); log rank = 0.64, df = 1, P > 0.05). In
contrast, there were significant differences found between
patients without medication and patients medicated before
their first alcohol use, on the one hand, and patients who
received medication after their first alcohol use, on the
other (Fig. 1(b); log rank = 32.27, df = 1, P < 0.001 and
log rank = 32.27, df = 1, P < 0.001, respectively). Also,
the cumulative probability of abstinence was higher for
patients taking disulfiram than for patients taking acamprosate
(Fig. 1(c); log rank = 11.78, df = 1, P < 0.001).
DISCUSSION
The aims of the present naturalistic, prospective, multisite
study were to examine: (i) which patient characteristics are
associated with pharmacotherapy for relapse prevention; (ii)
whether prescribing medication is associated with outcome
indices; and (iii) whether acamprosate and disulfiram are
related to outcome indices in different ways.
Pharmacotherapy condition, patient characteristics on admis-
sion and during index stay
Compared to patients without pharmacotherapy, about 20%
more patients with pharmacotherapy had SUD inpatient treat-
ment in the 2-year period before the index stay, and about
11% more patients with pharmacotherapy used alcohol dur-
ing the index stay, which suggests that these patients suffered
from more severe alcohol dependence. However, the two
groups did not differ with respect to other AUD or psychi-
atric disorder indices, frequency of other service utilization, or
demographic variables. In addition, patients medicated after
their first relapse generally consumed larger quantities of alco-
hol before index stay than patients medicated before their
first alcohol use. It would appear that medication is more
readily prescribed to patients who do not benefit from residen-
tial AUD treatment, despite their having repeatedly utilized
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Fig. 1. Comparison of (a) pharmacotherapy versus no pharmacotherapy;
(b) no pharmacotherapy versus pharmacotherapy before/after first alcohol
use; and (c) disulfiram versus acamprosate. Note: Tests of significance are
reported in the text.
SUD inpatient services. It may be the case that clinicians
do not regard pharmacotherapy as a treatment option unless
intensive psychosocial interventions have proved unsuccess-
ful. The severity of AUD and psychiatric symptoms alike, as
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well as craving and treatment motivation, all appear to be of
lesser relevance for prescription than the failure of inpatient
treatment.
Patients exhibiting symptoms of more severe alcohol
dependence on admission were more frequently prescribed
acamprosate than disulfiram. Clinicians may have based their
decision in favour of acamprosate on safety grounds, argu-
ing that heavily dependent patients would use alcohol in spite
of taking disulfiram. In as much as the clinicians concerned
were not queried on their reasons for prescribing a particular
medication to alcohol-dependent patients, this point remains
unclear. Pertinent research would shed light on clinicians’
decision-making processes and serve to improve these as
necessary.
Pharmacotherapy, treatment service utilization, and outcomes
at 1-year follow-up
Overall, compared to patients without pharmacotherapy, 25%
more patients receiving pharmacotherapy had at least once
used alcohol, 37% more of these patients had at least
1 alcohol relapse, and 30% more of these patients had
at least one SUD residential treatment. Specifically at the
1-year follow-up, patients receiving medication also reported
slightly greater alcohol use per regular drinking day and more
severe alcohol dependence symptoms, as well as less time
to their first alcohol use during the follow-up period, all
of which suggests that pharmacotherapy is associated with
worse AUD outcome indices. However, if the comparison
focuses on patients without medication and patients who
were prescribed medication before their first alcohol use,
no significant difference between the two patient groups
with respect to the course of alcohol use is found. Indeed,
the latter group reported fewer relapses and presented a
reduced need for SUD inpatient treatment than patients
medicated after their first alcohol use. Thus, worse AUD
outcome indices were only associated with patients who did
not receive medication until after their first alcohol use.
Appropriately timed prescribing practices would therefore
appear to prevent or delay alcohol use in patients who
had repeatedly received inpatient treatment to no avail,
pharmacotherapy having thereby an effect similar to that of
successful inpatient treatment. Further research is needed to
examine the reasons why clinicians do often not prescribe
medication upon discharge from residential treatment and for
less severely alcohol-dependent patients.
At the 1-year follow-up, compared to patients without
pharmacotherapy, 30% more patients with pharmacotherapy
reported SUD outpatient treatment and 14% more outpatient
treatment for other psychiatric disorders than by patients
without pharmacotherapy. They were also somewhat more
motivated for treatment. These findings are in line with
AUD treatment guidelines, according to which medication
for relapse prevention should only be prescribed to patients
who are motivated to take their medication regularly under
supervision during outpatient treatment (Mann, 2004).
No differences between the two groups with respect to
emotional distress or psychotic symptoms were found, and,
consequently, referrals for further psychiatric inpatient treat-
ment were unnecessary. Psychiatric symptoms do not appear
to be associated with medication for relapse prevention, nei-
ther on admission to index stay nor at the 1-year follow-
up.
Acamprosate, disulfiram, and alcohol use outcome
Disulfiram is associated with a longer time to first alcohol use
and a higher cumulative abstinence rate than acamprosate.
This concords with a meta-analysis conducted by Berglund
that revealed the effectiveness of supervised administration
of disulfiram (Berglund, 2005). If patients are struggling to
achieve abstinence, disulfiram is still warranted, provided that
the patients are supervised and side-effects are monitored.
On admission, however, more severely alcohol-dependent
patients are generally prescribed acamprosate rather than
disulfiram; disulfiram administration is more closely super-
vised than acamprosate. These two factors may also contribute
to the finding that patients receiving acamprosate did less well
than patients receiving disulfiram.
Limitations
Two caveats should be noted. First, the authors’ evaluation
utilized a prospective, naturalistic design that capitalized
on representative treatment conditions and typical treatment
orientations in a selection of Swiss programmes. Naturalistic
designs mirror actual conditions of treatment selection and
treatment processes, thereby augmenting the external validity
of the evaluation (Moos et al ., 1990b; Seligman, 1995).
However, data are derived from self-reports rather than
from reports from collaterals or biochemical markers of
alcohol use. Del Boca and Darkes note that self-report
measures, which are relatively inexpensive, non-invasive, and
acceptable to respondents, have yielded reasonable levels
of reliability and validity (Del Boca and Darkes, 2003).
Reliability and validity are further enhanced if patients are
assessed by research staff that are not directly associated
with the treatment programme, as was the case in the present
study.
Second, assuming that prescription rules are followed, it is
not known on which grounds clinicians base their decisions
to prescribe medication to alcohol-dependent patients. One
such criterion may be individual patients’ continued strug-
gle to achieve abstinence despite several SUD residential
treatments. Further research into clinicians’ decision-making
processes is required in order to identify the implicit criteria
applied in prescribing pharmacotherapy. This is of consid-
erable relevance because appropriately timed prescription of
medication was associated with longer periods of abstinence
in the present naturalistic study, and is furthermore related to
better SUD outcomes in a number of randomized controlled
studies (Miller and Wilbourne, 2002; Berglund, 2005; Anton
et al ., 2006).
In summary, medication for relapse prevention is more
likely to be prescribed for more severely alcohol-dependent
patients. While pharmacotherapy can prevent or delay alcohol
use under field conditions, it is often prescribed only after
first alcohol use or after relapses have occurred. Time of
abstinence proved longer, and the abstinence rate higher,
for disulfiram administered under supervision (i.e. in the
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course of outpatient treatment) than for acamprosate. Further
studies need to examine the reasons why pharmacotherapy
is not prescribed by clinicians upon patients’ discharge from
residential treatment and for less severely alcohol-dependent
patients.
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